Literature DB >> 25255394

Country of birth modifies the associations of body mass and hemoglobin A1c with office blood pressure in Middle Eastern immigrants and native Swedes.

Louise Bennet1, Peter M Nilsson.   

Abstract

OBJECTIVE: Immigrant populations from the Middle East are at high risk of obesity and diabetes, but paradoxically hypertension is reported to be less prevalent. Studies of the risk factors for hypertension in these populations are scarce. The aim was to study the distribution of cardiovascular and metabolic risk factors in the Middle East immigrant population compared with native Swedes.
METHODS: A population-based, cross-sectional study of men and women, aged 30-75 years, born in Iraq or Sweden, was conducted in 2010-2012 in Malmö, Sweden. A 75-g oral glucose tolerance test was performed, and sociodemographic and lifestyle data were collected.
RESULTS: In participants born in Iraq (n = 1311) vs. participants born in Sweden (n = 698), without a history of cardiovascular disease (CVD), the metabolic syndrome (MetS) was more prevalent in the Iraqis (49.2 vs. 40.3%, P < 0.001). Iraqis presented with higher prevalence rates of all but one MetS entity: elevated blood pressure (BP; 46.0 vs. 61.3%, P < 0.001, data adjusted for age, sex and antihypertensive medication). Being born in Iraq independently decreased the risk of elevated SBP and DBP. Furthermore, higher BMI, waist circumference, pulse rate and hemoglobin A1c (HbA1c) values presented weaker associations with SBP and DBP in Iraqis than in Swedes. These relationships were confirmed by interactions with the country of birth.
CONCLUSION: BP-regulating mechanisms seem to differ in the Middle Eastern compared with a nonmigrated native European population. Further studies are needed for reaching a better understanding of the mechanisms contributing to CVD in populations of mixed ethnic backgrounds.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25255394     DOI: 10.1097/HJH.0000000000000345

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

1.  Target Organ Damage and Cardiovascular Risk in a Hypertensive Roma Sample Population in Romania.

Authors:  Emma Weiss; Elisabeta Badila; Cristina Japie; Ana Maria Balahura; Daniela Bartos
Journal:  Maedica (Bucur)       Date:  2018-06

Review 2.  Cardiovascular risk assessment in South and Middle-East Asians living in the Western countries.

Authors:  Sahrai Saeed; Alka M Kanaya; Louise Bennet; Peter M Nilsson
Journal:  Pak J Med Sci       Date:  2020 Nov-Dec       Impact factor: 1.088

3.  Diabetes Mellitus and Its Risk Factors among Migrant Workers in Kuwait.

Authors:  Anwar Ali; Shaikhah Alfajjam; Janvier Gasana
Journal:  Int J Environ Res Public Health       Date:  2022-03-25       Impact factor: 3.390

4.  Favorable fatty acid composition in adipose tissue in healthy Iraqi- compared to Swedish-born men - a pilot study using MRI assessment.

Authors:  Lena Trinh; Karin G Stenkula; Lars E Olsson; Jonas Svensson; Pernilla Peterson; Louise Bennet; Sven Månsson
Journal:  Adipocyte       Date:  2022-12       Impact factor: 4.534

5.  Which anthropometric measures best indicate type 2 diabetes among Russian, Somali and Kurdish origin migrants in Finland? A cross-sectional study.

Authors:  Natalia Skogberg; Tiina Laatikainen; Annamari Lundqvist; Eero Lilja; Tommi Härkänen; Päivikki Koponen
Journal:  BMJ Open       Date:  2018-05-17       Impact factor: 2.692

Review 6.  Metabolically Healthy Obesity (MHO)-New Research Directions for Personalised Medicine in Cardiovascular Prevention.

Authors:  Peter M Nilsson; Johan Korduner; Martin Magnusson
Journal:  Curr Hypertens Rep       Date:  2020-02-17       Impact factor: 5.369

7.  Mortality in first- and second-generation immigrants to Sweden diagnosed with type 2 diabetes: a 10 year nationwide cohort study.

Authors:  Louise Bennet; Ruzan Udumyan; Carl Johan Östgren; Olov Rolandsson; Stefan P O Jansson; Per Wändell
Journal:  Diabetologia       Date:  2020-09-26       Impact factor: 10.122

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.